Cargando…

Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer

BACKGROUND: Expression of programmed death-ligand 1 (PD-L1) has been reported to correlate with response to immune checkpoint inhibitors (ICIs) in various tumor types. However, there are few data on the role of PD-L1 expression as a predictive and prognostic biomarker of sensitivity to ICIs in patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hongsik, Kim, Ryul, Jo, Hyunji, Kim, Hye Ryeon, Hong, Joohyun, Ha, Sang Yun, Park, Joon Oh, Kim, Seung Tae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386848/ https://www.ncbi.nlm.nih.gov/pubmed/35992188 http://dx.doi.org/10.1177/17562848221117638

Ejemplares similares

Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer
por: Kim, Hongsik, et al.
Publicado: (2021)

HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer
por: Kim, Hongsik, et al.
Publicado: (2022)

The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers
por: Kim, Hye Ryeon, et al.
Publicado: (2021)

The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation
por: Jeong, Sun Young, et al.
Publicado: (2023)

Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI
por: Kim, Hye Ryeon, et al.
Publicado: (2023)

Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach
por: Kim, Hana, et al.
Publicado: (2021)

Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer
por: Seo, Hye-Rim, et al.
Publicado: (2022)

A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma
por: Jo, Hyunji, et al.
Publicado: (2022)

MicroRNA 141 Expression Is a Potential Prognostic Marker of Biliary Tract Cancers
por: Kim, Jaihwan, et al.
Publicado: (2016)

The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer
por: Lee, Su Jin, et al.
Publicado: (2018)

The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC)
por: Heo, Mi Hwa, et al.
Publicado: (2017)

Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing()
por: Yoo, Kwai Han, et al.
Publicado: (2016)

Therapeutic implication of HER2 in advanced biliary tract cancer
por: Nam, Ah-Rong, et al.
Publicado: (2016)

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Diagnostic Role of Bile Pigment Components in Biliary Tract Cancer
por: Ahn, Keun Soo, et al.
Publicado: (2023)

Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer
por: Nam, Ah-Rong, et al.
Publicado: (2019)

Long-Term Breast Cancer Outcomes of Pregnancy-Associated Breast Cancer (PABC) in a Prospective Cohort
por: Jo, Hyunji, et al.
Publicado: (2022)

Immune Checkpoint PD-1/PD-L1 CTLA-4/CD80 are Blocked by Rhus verniciflua Stokes and its Active Compounds
por: Li, Wei, et al.
Publicado: (2019)

Age-Specific Cutoffs of the Sysmex UF-1000i Automated Urine Analyzer for Rapid Screening of Urinary Tract Infections in Outpatients
por: Kim, Hyunji, et al.
Publicado: (2019)

The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
por: Kim, Hana, et al.
Publicado: (2021)

Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer
por: Nam, Ah-Rong, et al.
Publicado: (2020)

When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer
por: Kim, Hongsik, et al.
Publicado: (2021)

Risks of colorectal cancer and biliary cancer according to accompanied primary sclerosing cholangitis in Korean patients with ulcerative colitis: a nationwide population-based study
por: Oh, Eun Hye, et al.
Publicado: (2023)

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection
por: Kim, Young Saing, et al.
Publicado: (2017)

Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors
por: Kim, Hye Ryeon, et al.
Publicado: (2022)

Establishing Patient-Derived Cancer Cell Cultures and Xenografts in Biliary Tract Cancer
por: Kang, Jihoon, et al.
Publicado: (2023)

Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
por: Park, Joon Oh, et al.
Publicado: (2015)

Comprehensive immunoprofile analysis of prognostic markers in pancreaticobiliary tract cancers
por: Kim, Ji Eun, et al.
Publicado: (2023)

High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
por: Ahn, Soomin, et al.
Publicado: (2020)

Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response
por: Li, Jingjing, et al.
Publicado: (2020)

Conversion surgery for initially unresectable extrahepatic biliary tract cancer
por: Oh, Moon Young, et al.
Publicado: (2021)

Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

P267 Candida in the biliary tract: extrapolative PK PD considerations
por: Rege, Sujata, et al.
Publicado: (2022)

Predictive Factors of Biliary Tract Cancer in Anomalous Union of the Pancreaticobiliary Duct
por: Park, Jin-Seok, et al.
Publicado: (2016)

Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer
por: Seesaha, Poshita-Kumari, et al.
Publicado: (2021)

Identification of potential biomarkers for diagnosis of pancreatic and biliary tract cancers by sequencing of serum microRNAs
por: Kim, Kwondo, et al.
Publicado: (2019)

Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy
por: Cho, Kyoung-Min, et al.
Publicado: (2017)

Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions
por: Kim, Eun-Hye, et al.
Publicado: (2020)

A Case of Biliary Cystadenocarcinoma
por: Suh, Jeong III, et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_j09r12kipv6hggubpb7a8ar69l